Skip to main content
. 2018 Jan 23;11:1756285617753365. doi: 10.1177/1756285617753365

Figure 3.

Figure 3.

Proportion of patients with no T1 gadolinium-enhanced lesions in the cladribine tablet 3.5 mg/kg in CLARITY/placebo in CLARITY Extension and 5.25 mg/kg groups during CLARITY Extension according to gap duration.

Error bars indicate 95% confidence intervals.

CP, cladribine tablet in CLARITY/placebo in CLARITY Extension; Gd+, gadolinium enhanced.